Pathology: endometrial cancer; endometrial cancer - (neo)adjuvant (NA);
endometrial cancer | endometrial cancer - (neo)adjuvant (NA) | |||||
KEYNOTE-775, 2023 | LEAP-001/ENGOT-en9, 2024 | NRG-GY018_pMMR, 2023 | NRG-GY018_dMMR, 2023 | KEYNOTE-B21, 2024 | ||
pembrolizumab plus SoC | 3 | T1 | T1 | T1 | ||
pembrolizumab plus lenvatinib | 2 | T1 | T1 | |||
Standard of Care (SoC) | 0 | T0 | T0 | |||
placebo plus SoC | 0 | T0 | T0 | T0 |